AVITA Medical (NASDAQ:RCEL) & Allurion Technologies (NYSE:ALUR) Head-To-Head Comparison

AVITA Medical (NASDAQ:RCEL) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Volatility and Risk

AVITA Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.37, suggesting that its stock price is 137% less volatile than the S&P 500.

Profitability

This table compares AVITA Medical and Allurion Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AVITA Medical	-95.47%	-194.69%	-60.67%
Allurion Technologies	-71.24%	N/A	-56.75%

Valuation & Earnings

This table compares AVITA Medical and Allurion Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AVITA Medical	$50.14 million	6.70	-$35.38 million	($2.23)	-5.75
Allurion Technologies	$53.47 million	0.46	-$80.61 million	($0.48)	-0.79

AVITA Medical has higher earnings, but lower revenue than Allurion Technologies. AVITA Medical is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for AVITA Medical and Allurion Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AVITA Medical	0	2	1	0	2.33
Allurion Technologies	0	1	3	1	3.00

AVITA Medical presently has a consensus target price of $16.50, indicating a potential upside of 28.71%. Allurion Technologies has a consensus target price of $2.88, indicating a potential upside of 656.58%. Given Allurion Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than AVITA Medical.

Insider and Institutional Ownership

27.7% of AVITA Medical shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 1.8% of AVITA Medical shares are held by company insiders. Comparatively, 22.4% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Allurion Technologies beats AVITA Medical on 11 of the 15 factors compared between the two stocks.

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.